This Week's Top Stories: GLP-1 Dominance, Buffett's Oil Play, and the Meta Verdict

The week's best-performing editorial — curated for the weekend. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

April 4, 2026 FDA Clears Eli Lilly's Weight-Loss Pill – Here's Why GLP-1 Dominance Just Got Priceless Eli Lilly secured FDA approval for Foundayo, its once-daily oral GLP-1 weight-loss pill. Already the dominant player in injectables, it now challenges Novo Nordisk's early oral entry in a rapidly expanding market. Read more. › Sponsored New Musk Product Worth 684X Starlink? Early Starlink investors could have turned $1,000 into over $64.5 million. But Wall Street's latest estimates say Musk's new AI product could be worth 684X Starlink — and Jeff Brown says it could send this tiny Musk-linked ticker soaring as soon as April 24. Click here for the full story. › Brent's Record Surge Meets Buffett's Favorite Oil Stock Warren Buffett has been quietly loading up on Occidental Petroleum as oil prices surge. With Brent hitting new highs and supply disruptions mounting, OXY may be the smartest energy play in the market right now. Read more. › Sponsored The AI Apocalypse Is Coming for Your Portfolio Dr. Martin Weiss says a massive AI-driven market disruption is already underway. Most investors are completely unprepared. He's identified the one sector that will collapse first — and the moves to make before it happens. Get the details here. › Meta Platforms Addiction Lawsuit Verdict: Buy or Sell? A landmark addiction lawsuit verdict has rocked Meta Platforms. But with ad revenue surging, AI momentum building, and the stock already absorbing the news, this sell-off may be exactly the opportunity contrarians have been waiting for. Read more. › You are receiving this e-mail at lestyantoro14@gmail.com, as part of your subscription to Money Morning. Manage Your Preferences by clicking here. No longer interested? Unsubscribe. © 2026 Money Morning. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication prior to following an initial recommendation. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Agora Media, 14 West Mt Vernon Place, Baltimore, MD 21201. Money Morning is a First Light Financial, LLC publication. To contact us call 866-616-2166 or visit us online. Website  |  Privacy Policy  |  Terms & Conditions